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ABSTRACT
The human immunodeficiency virus, a retrovirus discovered in 1981, has reached
pandemic status worldwide. Without an existing cure or vaccine, a majority of the world’s
population remains at risk for infection and more than 35 million people to date have died from
AIDS. Resistance to the virus, however, has been discovered in about 10% of the world’s
population in the form of an allelic base pair deletion, located on C-C chemokine receptor 5.
Those homozygous for the base pair deletion are resistant to HIV, while heterozygotes have
displayed delayed onset of HIV infection. The CCR5 mutation and observed resistance to HIV in
those with the base pair deletion represent exciting possibilities for the prevention and treatment
of the virus. A new class of pharmaceuticals termed CCR5 antagonists, as well as CCR5-∆32
allogenic stem cell transplantation, hold therapeutic promise not just for HIV but also other
chemokine mediated inflammatory diseases, including multiple sclerosis, rheumatoid arthritis,
cancer and autoimmune myocarditis.
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Introduction
Since the discovery of the human immunodeficiency virus in 1981, scientists have
explored every aspect of the virus in the hope of finding a cure. Although this cure or vaccine
has yet to be discovered, some hope exists in the recent discovery of a genetic mutation that
results in resistance to HIV. C-C chemokine receptor 5 (CCR5) is the cellular locus where the
HIV virus enters the cell (5). Some individuals, however, have a 32 base pair deletion at the
CCR5 receptor site, resulting in complete resistance to HIV in those homozygous for the deletion
and partial resistance or delayed onset of infection in those heterozygous for the deletion (5). The
absence of these 32 nucleotides at the CCR5 receptor site results in a truncated, non-functional
protein, making it impossible for HIV to enter the human host cell without a necessary
coreceptor.
Population surveys have found the overall frequency of this allelic mutation to be as
high as 10% among those of European descent, but have not found any individuals of African,
Middle Eastern or Asian descent possessing the deletion (11). Because the human
immunodeficiency virus evolved relatively recently in history, there is strong a suggestion that
the mutation was selected for prior to the emergence of HIV by other factors (14). Among these
suggestions are the bubonic plague and smallpox, all of which have been hypothesized as
historical selective pressures for the mutation.
While the exact historical origin of the CCR5-∆32 deletion has yet to be confirmed, the
ways in which this base pair mutation influences host defenses presents a hope for HIV and
AIDS research. By targeting C-C chemokine receptor 5, a new class of pharmaceuticals termed
CCR5 antagonists represent potential for the prevention and treatment of HIV, as well as
therapeutic potential for other chemokine mediated inflammatory diseases, including multiple
sclerosis, rheumatoid arthritis, cancer and autoimmune myocarditis.
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Chemokines and Their Receptors: Structure and Function
The C-C chemokine receptor 5 molecule involved in HIV-1 resistance is one in a
class of molecules termed chemokine receptors. True to their name, chemokine receptors act as
the body’s receptors for chemokines, small cytokine molecules that promote chemotaxis, or
movement within the cell (10). Chemokines are divided between two different classes: those
involved in inflammation, pro-inflammatory chemokines, and those involved in tissue
maintenance, or homeostatic chemokines (16).These pro-inflammatory chemokine molecules
play an important role in the immune system, acting as recruiters and activators for a variety of
immune system cells, such as lymphocytes, monocytes, macrophages, eosinophils, and basophils
(2). Pro-inflammatory chemokines are responsible for directing host responses to foreign
particles by mediating inflammation, and as such are one of the first molecules involved in the
inflammatory process.
Chemokines are divided into two different classes: CC chemokines, or β-chemokines,
which primarily attract neutrophils, and CXC chemokines, or α-chemokines, which attract
monocytes and lymphocytes (2). While the structure varies slightly between the two classes of
chemokines, what remains common among all chemokines is the transmembrane structure of
their receptors. This 7-transmembrane structure on the leukocyte cellular surface contains both
extracellular and intracellular loops, allowing the chemokine receptor to bind with glycoproteins,
or G proteins. Once bound to a G protein, the chemokine receptor is considered to be activated,
meaning that it can transmit signals to the cell (10).
CCR5 Structure
The structure of the CCR5 chemokine receptor, like all chemokine receptors, has the
characteristic 7 transmembrane structure, with 3 extracellular and 4 intracellular loops. The
CCR5 receptor ligand also contains an extra-cellular N-terminal domain, involved in receptor
signaling, and an intracellular C-terminal domain (10). When chemokine molecules bind to the
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CCR5 receptor, a conformation change occurs allowing the activation of the G protein coupled
to the receptor and the consequential initiation of cellular signaling (10).
CCR5 and HIV-1
The CCR5 chemokine receptor is of particular interest to researchers because of its
role as a coreceptor for HIV. HIV, the virus responsible for acquired immunodeficiency
syndrome (AIDS) was first identified by scientists in 1981 and has since killed more than 35
million people, the majority of which live in Sub-Saharan Africa (3). 33 million people globally
are currently living with the virus (15). HIV is divided into two subtypes: the HIV-1 virus, which
is responsible for the majority of all HIV infections, and HIV-2, a less frequent, less-readily
transmitted variation of the virus, confined mainly to Western Africa (3).
HIV-1 Pathophysiology
Although HIV-1 is as an infectious disease, it is not as highly contagious as many other
infectious pathogens; it is not transferrable through fomites, or inanimate objects such as door
handles, nor can it be spread by insects, such as mosquitoes in the case of malaria or West Nile
virus (19). The only way the HIV-1 virus can be spread is through transmission of bodily
fluid from an infected individual, namely blood, breast milk, vaginal secretions, and semen
containing a sufficient concentration of the virus to result in infection (19).
Once in the human body, the HIV-1 virus attacks the host’s lymphocytes, specifically
T-lymphocyte cells. The HIV-1 infectious process can be divided into two different stages,
the M-tropic (primary) and T-tropic (latter) stages (2). In the M-tropic stage, two viral
glycoproteins on the HIV capsid (gp41 and gp120) bind to a receptor molecule, CD4, on the Tlymphocyte cell (19). When the virus attaches to the CD4 molecule, gp120 undergoes a
conformational change that exposes binding sites allowing it to bind to the chemokine receptor
CCR5 (10). Once HIV has bound itself to both the CD4 and CCR5 coreceptor molecules, the
virus undergoes yet another conformational change, allowing the hydrophobic regions of gp41 to
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insert themselves into the membrane of the host cell (10). Gp41 then folds itself into a 6-helix
bundle, bringing the viral membrane and the host cell membrane into closer contact, with the two
membranes ultimately fusing together and the HIV viral contents entering the host cell (10).
Once inside, the HIV virus matures and replicates in the host cell, ultimately budding off
of the host cell in order to infect other T-cells, resulting in the characteristic depletion of Tlymphocytic cells in HIV-1 positive individuals (19). This depletion of T-cells is part of the Ttropic stage, characterized by a continually declining number of T-cells in the body. In an
uninfected individual, the T-cell count is typically around 1,000/mm3 of blood; in an infected
individual, the count decreases by 40 to 80 cells per year (19). Once the T cell count has reached
400 to 800 cells/mm3 of blood the body’s immune system has been significantly compromised.
Opportunistic infections, such as thrush and shingles, set in and the individual is said to have
AIDS-related complex (or ARC) (19).
The CCR5 - ∆32 Basepair Deletion
When the role of chemokine receptors in the infectious process of HIV was revealed in
1995, genetic variants in the CCR5 chemokine receptor discovered one year later in 1996 proved
the HIV-1 virus is not universally infectious (15). A genetic variation of the CCR5 gene
showed that certain individuals have a 32 base pair deletion in the molecular structure of the
chemokine receptor, a mutation that shifts the allele’s open reading frame, resulting in a
truncated protein (15).
For those individuals homozygous for the deletion, that is to say, with two copies of the
gene mutation, the chemokine receptor CCR5 is not fully produced by the body and is absent
from the cell surface (2). Without CCR5 coreceptor expression at the surface of the host cell, the
HIV-1 virus cannot attach to the host cell or insert its viral DNA, making the individual
effectively resistant to HIV-1 infection. Individuals heterozygous for the deletion, possessing
only one copy of the mutation, have a reduced number of CCR5 coreceptors expressed at the
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cellular surface, a reduction which slows the progression of HIV (2). In addition to the delayed
progression of HIV, heterozygotes for the ∆32 mutation have also displayed a reduced viral
load. The reduction in the number of CCR5 coreceptors at the cellular surface translates to
reduced opportunistic portals for the HIV-1 virus, as well as decreased T-cell destruction (15).
Global Distribution of the CCR5 - ∆32 Mutation
When examining the global distribution of the ∆32 deletion, certain geographical trends
become very obvious. The ∆32 mutation is found only in those of European and Western Asian
(Russian) origin and exhibits a north-south cline, meaning frequencies of the allele are highest in
northern Europe and gradually decline towards the more southern regions (14). For example, the
frequency of the allele ranges from 16% in northern Europe (Sweden, Finland, Belarus, Estonia
and Lithuania) to 4% in Greece (14). The highest observed frequency of the allele, 20.93%, can
be found amongst Ashkenazi Jews, but is most likely a founder effect due to the fact that the
Ashkenazi population is highly endogamous (12,14).
The frequency of the ∆32 deletion in European populations, as well as its total absence in
Asia, Africa, and the Middle East, is important not only in understanding the origins of the
mutation but for discovering ways in which population genetics can be used to understand
how the gene was selected for. The absence of the allele in Asian, African and Middle Eastern
populations suggests that the mutation arose after these populations diverged (10), and the high
allelic frequency observed in certain populations indicates selective advantages for the ∆32
deletion other than HIV (10).
Origins of the Mutation
Because of the way the CCR5 - ∆32 allele is globally distributed, evidence
points to a single mutation event as the origin for the mutation (7). Since allele frequencies are
highest in Caucasian population and nonexistent in others, the ∆32 deletion indicates an origin
dating to sometime after the divergence of various populations from their shared African origin
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(7). Additional evidence in support of the single mutation event theory stems from the size of the
deletion – a 32 base pair deletion is a large deletion, meaning that it is highly unlikely to have
occurred more than once within the last 1,000 years (7).
Age of the Allele
While a single origin of the allele is almost universally agreed upon by researchers, the
exact age of the mutation has been a subject of mass debate. Inferences as to the age of the allele
have been drawn from the archeological findings from a burial site in Lichtenstein, France –
here, a Bronze Age skeleton dating to 900 B.C. The remains of 17 individuals at this site were
genetically analyzed and found to demonstrate an allele frequency of 11.8% for the ∆32 deletion
(8), indicating that the CCR5 - ∆32 allele was prevalent among prehistoric populations of central
Europe (8).
Another popular hypothesis regarding the age of the ∆32 deletion has centered around the
possible role of the Vikings in its dispersal. The frequency of the allele in Nordic countries such
as Norway, Sweden, and Iceland (as high as 16%), suggests that the Vikings may have
disseminated the mutation during the raiding of Northern Europe from the 8th to 10th centuries
(11).
Historical Selective Pressures for the ∆32 Mutation
Because approximately 85-95% of human genetic variation is shared among African,
Asian and European populations, the genetic variation seen between these populations regarding
the CCR5-∆32 deletion suggests not only the recent origin of the allele but also influence from a
historical selective pressure (22). The frequencies of the allele observed in Europe also indicate
the presence of selective pressures – for the ∆32 mutation rate to reach a rate of 10% without any
influence from selective pressures would take 127,500 years (7). Additional support for the
selective pressure hypothesis stems from the fact that genes encoding proteins for reproductive
and developmental functions that maximize survival fitness are shared among various ethnic
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populations; those encoding immunological functions are usually pathogenically or historically
selected for (22).
Bubonic Plague and Small Pox
Because the HIV-1 virus is believed to have evolved relatively recently in human history,
it has not been a exerting selection on the human genome long enough to be considered as
selective pressure for the ∆32 mutation (7). The two most commonly suggested historical
selective pressures for the CCR5 - ∆32 deletion are smallpox and plague.
Bubonic Plague
Because of the relatively young age of the allelic mutation, many have suggested that
bubonic plague, namely the outbreak that caused the Black Death of 1346 – 1352 is responsible
for the frequencies seen in European populations (1,17,18,21). The bubonic plague, caused by
the bacterium Yersina pestis (Y. pestis), is a diseases caused by rodents. Outbreaks of the disease
must first originate with an epizootic within a rodent population (1). Once large numbers of
rodents have died off, the fleas that normally feed off of the rodent populations move to humans
in order to obtain blood (1). For bubonic plague to result from the flea bite, the flea must
regurgitate the Y. pestis bacillus into the blood stream of the human which it is feeding upon (1).
Because the success rate for the transmission of the Y. pestis bacillus into the human
blood stream from a flea bite is less than 20%, the disease spreads through populations slowly
(1), and is wholly dependent on the activity levels of the fleas spreading the disease (4). The
rodents so commonly associated with the disease, therefore, are simply intermediaries – for
bubonic plague to spread, the infected wild rodent population must die and then pass on the fleas
carrying the infection (4).
Once the human has been bitten by the Y. pestis carrying flea, they enter an incubation
period of two to six days (4). Around the sixth day they experience chills and a fever, as well as
severe headaches and body aches (4). The infected person then becomes very confused and
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restless, often slurring their speech – within two days of these symptoms setting in, they are
prostrate with the symptoms of shock, and will usually die sometime between the third and the
sixth day (4).
The aggressive pathology of the bubonic plague explains the high mortality rates
observed in Europe at the time of the outbreaks. At least a third of Europe’s population died
during the Y. pestis outbreak of 1346 – 1352, and some cities, such as Florence, experienced a
75% decline in their population owing to plague mortality (1). In an attempt to explain high
levels of the CCR5 - ∆32 base pair deletion among Europeans, some scientists have argued that
this Black Death outbreak caused a genetic shift in the population of Europe resulting in the
HIV-1 resistance observed today (4).
While theories connecting the Black Death to the frequency rates of the ∆32 mutation
have been proposed, modern research regarding bubonic plague’s roles in the mutation prove
that it most likely was not the cause behind the rise in ∆32 allelic frequencies. In recent
laboratory experiments, the connections between Y. pestis and CCR5 have been tested to see if a
correlation between the two does exist. In these experiments, CCR5 deficient mice, a deficiency
that mirrors the absence of the CCR5 chemokine receptor on human cell surfaces in the presence
of the ∆32 mutation, were inoculated with Pgm, the Y. pestis KIM substrain D27 (13). Two to
four days post-inoculation, there was no difference between bacterial load in CCR5 deficient
mice and CCR5 expressing mice (13). These laboratory results proved that not only does the Y.
pestis bacterium not use the CCR5 receptor (4), but also that CCR5 deficiency in mice does not
reduce the chance of infection or death from Y. pestis infection, meaning it is unlikely that the
∆32 allelic mutation provides plague protection.
Evidence suggesting a selective factor other than bubonic plague also cites plague rates
during the 14th through 17th centuries. The Black Death outbreak infamous for killing one third
of the European population was a single pandemic – no other large outbreaks of the plague (with
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the exception of one in 1665) occurred in Europe after the 14th century, meaning that at most
allelic frequency for the CCR5 - ∆32 mutation would have increased from a frequency of 5 x
10-5 to 5 x 10-4 (5). Using a model combining population genetics with the dynamic of bubonic
plague, two researches, Galvani and Slatkin, developed a model proving that the intermittent
nature of the plague epidemics in Europe were not a strong enough selective factor to drive
allelic frequencies to that rates of ~ 10% observed in Europe today (6,7).
Smallpox
Because bubonic plague and the Y. pestis bacillus were not present in Europe long
enough to be considered as a selective factor for the CCR5-∆32 mutation, it is likely that
selection in favor of the base pair deletion occurred because of a disease that was endemic to the
European population. Smallpox, a disease that occurred in epidemics in Europe at least once
every five years from 1347 to 1979, was once such endemic disease (5). While the Black Death
may have killed 23 million people during the main outbreak of the disease in the 14th century,
smallpox killed more than 300 million people until it was eradicated in 1979 (2).
In addition to its status as a disease endemic to Europe during the time period during
which ∆32 was being selected for, it is also necessary to consider the way in which smallpox is
transmitted. Because smallpox is transmitted directly between humans (as opposed to the flea-tohuman transmission observed for bubonic plague), it was continuously transmitted between the
population of Europe during the time (6). The frequency of smallpox outbreaks meant that
children were typically the only immunologically naïve individuals in a community – most
Europeans experienced a smallpox infection before the age of 10 (7), with only 70% surviving an
infection (6). Smallpox, therefore, was exerting continuous selection for the CCR5 - ∆32
mutation over the European population (6) – only those children that survived the childhood
outbreaks of smallpox went on to reproduce and pass on selective factors to future generations.
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Other evidence pointing in favor to smallpox as the European disease that selected for
∆32 is the similarities between the etiologies of smallpox and HIV (2). Both smallpox and HIV
are viruses (as opposed to Y. pestis, which is a bacterial disease). The infectious process in both
HIV and smallpox uses chemokine receptors in order to infect lymphocytes, and the gene
products from pox viruses actually inhibit chemokine receptors (7). Indeed, one member of the
pox virus family, Myxoma virus, specifically targets the CCR5 receptor (2). Although the
specific receptors for smallpox have yet to be identified,it is possible that the similarities
between the pox viruses could translate to a shared inhibition of the CCR5 receptor, making
smallpox a definite candidate as the historical selective factor for HIV.
Just as the model used by Galvani and Slatkin to disprove the likelihood of bubonic
plague as a selective factor for the ∆32 mutation, the smallpox virus reaches allelic frequencies
of 10% in 680 years (2), almost the exact time period for which smallpox has been endemic in
Europe. This model, in combination with the similarities between smallpox and the HIV virus,
makes smallpox the more likely disease in European history presently serving as a selective
factor for the CCR5 - ∆32 deletion and HIV-1 resistance.
Potential Therapies Involving the CCR5 - ∆32 Deletion: HIV-1
Insight into the historical selective factors not only answers questions regarding how and
when the ∆32 mutation was selected for, but also a better understanding of why it was selected
for. Using the knowledge gained from these examinations, particularly connections to smallpox
etiology, provides information to researchers regarding the ways ∆32 can be used for potential
therapies for HIV or other diseases using chemokine receptors as disease pathways.
Current drug therapies for HIV involve a variety of pharmaceuticals. These antiretroviral
drugs (ARVs) include nucleoside/nucleotide reverse transcriptase inhibitors, non nucleoside
reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors and entry inhibitors (3).
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Recent pharmacological research, however, has focused on the ways in which chemokine
inhibition, similar to that observed in those homozygous for the ∆32 base pair deletion, can be
used to develop new therapies for HIV. Because the main mechanism of entry for the HIV virus
involves the CC chemokine receptor CCR5, it is the hope of researchers that two new CCR5
inhibitors (antagonists), maraviroc and vicriviroc, will help slow the progression of HIV to AIDS
by inhibiting viral entry into the host cells.
Maraviroc and Vicriviroc
Maraviroc, a CCR5 co-receptor antagonist, was first approved by the FDA in 2007, while
vicriviroc, also a CCR5 antagonist, is currently in phase III clinical trials (3). Maraviroc’s
mechanism of action centers around the host T-cell membrane, where the CCR5 receptor is
expressed. By inhibiting chemokine sub-type ligands CCL3 and CCL4, cystine groups at the Nterminal region of the CCR5 receptor, maraviroc blocks intracellular signaling and prevents the
interaction between the CCR5 receptor and the gp120 G-protein on the HIV-1 virus necessary
for insertion of viral information to the host cell (3). Vicriviroc, as a CCR5 antagonist, works in a
similar way to maraviroc, but has yet to be approved for public use by the FDA.
Aside from these two pharmaceuticals, other research has focused on ways to inhibit HIV
entry into the host cell by blocking or disrupting the synthesis of the CCR5 chemokine receptor
protein (3). Some of the ways in which researchers have decreased CCR5 expression at the
cellular surface have ranged from RNA interference (RNAi), a process that cleaves RNA in cells
to decrease the expression of certain proteins (3), to the use of zinc fingers, proteins that insert
themselves into DNA in order to block protein synthesis, such as the synthesis of the CCR5
receptor protein (3).
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Allogenic Stem Cell Transplantation
In addition to the development of CCR5 antagonists, researchers have also recently
discovered stem cell transplantation as a therapeutic option for HIV-1 patients. Because R5
tropic strains of HIV-1 must use the CCR5 coreceptor in order to enter the host cell,
transplanting stem cells from a donor homozygous for the ∆32 base pair deletion into an
individual without the deletion should result in the recipient acquiring the HIV-1 resistance
observed in the donor. In recent experiments with the procedure, a HIV-1 positive patient
received stem cells from an HLA matched ∆32 homozygous donor. The patient’s HAART
antiretroviral therapy was discontinued prior to transplantation (9). Cellular analysis posttransplantation revealed HIV-1 to be undetectable (9). In just 61 days, the patient’s genotype
changed from homozygous for absence of ∆32 base pair deletion(-/-) to a +/+ ∆32 homozygous
state in which the CCR5 receptor was completely absent from mucosal T-cells (9). At the time of
release of the study (2009 – 20 months post-transplantation), the patient still remained without
viral rebound (9).
Potential Therapies Involving the CCR5 - ∆32 Deletion: Chemokine Mediated Disease
While research into the ∆32 base pair deletion has provided many viable therapeutic
options for the HIV-1 virus, it has also demonstrated the ways in which other chemokine related
diseases can be manipulated. Like HIV, many other diseases - such as multiple sclerosis,
rheumatoid arthritis, cancer and autoimmune myocarditis – also use chemokines and chemokine
receptors as mediators of inflammation. By exploring the role of CCR5 in HIV-1, researchers
have gained a better understanding of how this receptor impacts the pathologies of numerous
other autoimmune diseases.
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Multiple Sclerosis
Multiple sclerosis is one such autoimmune disease that displays significant chemokine
involvement in its pathology. The demyleination of neuronal axons that causes the neurological
symptoms associated with the disease (muscle tremor, loss of sensation in the periphery,
difficulties with coordination, etc) is caused as a result of leukocyte infiltration into the central
nervous system (16). The CCR5 receptor was found on the lymphocytic cells in brain lesions of
MS patients, and was expressed at heightened levels by the T-cells in their cerebrospinal fluid
(16). The increased expression of CCR5 in CSF fluid of MS patients suggests an active role of
CCR5 in the immune response that causes neuronal demyleination.
Several recent studies have focused on how CCR5 suppression in MS patients via CCR5
antagonism could produce therapeutic benefits. While no study has been conclusive, CCR5-∆32
homozygous individuals with the disease provide clues as to how antagonism at the CCR5
receptor site could be beneficial to MS patients. The ∆32 deletion has not been shown to prevent
onset of the disease, but it has been shown to delay it, with ∆32 homozygous individuals
developing the disease up to 3 years later than their CCR5 expressing counterparts (16).
Rheumatoid Arthritis
Like MS, rheumatoid arthritis is also an autoimmune disease. While MS inflammation
centers around the myelin sheaths of neuronal axons, rheumatoid arthritis is characterized by
inflammation of the synovial joints, resulting in extreme difficulty and pain when moving these
joints. The inflammation of the synovial joints is caused by T lymphocyte infiltration, a process
mediated by chemokines (16). CCR5 has been found in the synovial fluid of patients with
rheumatoid arthritis - fibroblasts in the synovial joint upregulate CCL5, a ligand of the CCR5
receptor (16).
As with multiple sclerosis, heightened CCR5 expression at the inflammatory site suggests
the therapeutic benefits of CCR5 antagonism. Since the ∆32 deletion has been associated with
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decreased severity of the disease, CCR5 antagonists represent definite promise for rheumatoid
arthritis patients.
Cancer
Cancer cells, particularly pancreatic and prostate cancer cells, have also proved to be
possible sites where CCR5 antagonism would prove beneficial. Because cancer cells can induce
inflammation via chemokines (3), antagonism at the chemokine receptor site would reduce this
inflammation and prevent further tumor growth and metastasis (3). Some types of breast cancers
have also demonstrated increased metastasis in response to chemokines (3). CCR5 antagonism
could block the signaling associated with inflammation, preventing tumors from growing or
spreading to other areas of the body. One CCR5 antagonist, TAK-779, has proved especially
effective in preventing tumor proliferation and metastasis in prostate cancer cells (3). Further
research into the use of these drugs could potentiate future therapies for many other types of
cancers.
Autoimmune myocarditis
Autoimmune myocarditis is an autoimmune disease in which T cell infiltration promotes
inflammation of heart muscle tissue. In dissections of inflamed myocardial tissues, CCR5 was
found to be upregulated, once again suggesting its role in the disease’s pathology (3). In
experiments done with mice, CCR5 antagonism proved to reduce the severity of myocardial
inflammation, and those mice that lacked CCR5 expression (∆32 homozygous) showed
decreased incidence of the disease (3). Should these results were to carry over to humans in
further research, CCR5 antagonism could hold great therapeutic promise for patients with the
disease.
Conclusions
The CCR5 - ∆32 base pair deletion, in addition to providing HIV-1 resistance in
individuals homozygous for the mutation and delayed onset of AIDS in heterozygotes, holds
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promise for future research not only in HIV but also other chemokine-related disorders. By
studying the ways in which the ∆32 deletion affects chemokine mediated diseases, researchers
can gain a better understanding of the process of inflammation and intercellular chemotactic
signaling that results in disease. Manipulation of the chemokine system and resulting
inflammation through CC5R receptor antagonism has the potential to propagate a cure for
multiple autoimmune related diseases as well as inflammatory-based disease as a whole.
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FIGURES

Figure 1: The Structure of the CCR5 Chemokine Receptor. Here, the 7
transmembrane structure of the CCR5 receptor is displayed, with 3 extracellular
and 4 intracellular loops, as well as the extracellular N-terminal domain used for
receptor signaling.
Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its
role in HIV infection and treatment. JAMA 2006; 296:815-826.
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Figure 2: Entry of the HIV-1 Virus Into the Host Cell. The HIV-1 virus, via
gp120 and gp41, binds to coreceptors CD4 and CCR5, undergoing
conformational changes until the ultimate fusing and insertion of viral
information into the host cell.
. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and
its role in HIV infection and treatment. JAMA 2006; 296:815-826.
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Figure 3: The CCR5-∆32 Deletion. The 32 basepair deletion in the
CCR5 chemokine receptor, resulting in a truncated CCR5 receptor
protein and zero expression at the cellular surface.
De Silva E, Stumpf MPH. HIV and the CCR5 – ∆32 resistance allele.
FEMS Microbiology Letters 2004; 241:1-12.

Figure 4: Map Showing the Distribution of the CCR5-∆32 Allele.
. Lucotte G. Distribution of the CCR5 gene 32-basepair deletion in West
Europe: a hypothesis about the possible dispersion of the mutation by the
Vikings in historical times. Human Immunology 2001; 62:933-936.

20

Figure 5:: Maraviroc Structure.
Dhami H, Fritz CE, Gankin B, Pak SH, Yi W et al. The chemokine
system and CCR5 antagonists: potential in HIV treatment and other
novel therapies. J Clinical Pharm and Therapeutics 2009; 34:147160.

Figure 6:: Vicriviroc Structure.
Dhami H, Fritz CE, Gankin B, Pak SH, Yi W et al. The chemokine
system and CCR5 antagonists: potential in HIV treatment and other
novel therapies. J Clinical Pharm and Therapeutics 2009; 34:147-160.
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